epidemiologic impact of such prothrombotic states has not been clearly established in Mexico, we decided to evaluate the characteristics of these 2 pathologic phenomena in the country.
Subjects and Methods

Subjects
We conducted a cross-sectional, observational, nonrandomized study of indigenous and mestizo Mexican populations. To collect the whole number of blood samples according to the calculated sample size, we recruited subjects from 3 main sources, namely, governmental blood banks, universities, and nongovernmental organizations. In every case, direct contact with the source of individuals started before sampling. We provided the blood banks with careful information about the study the same day of blood donation and then asked the blood donors to participate. We obtained the sample immediately before blood donation. For universities and nongovernmental organizations, appropriate information was sent and distributed to the candidates to participate several weeks before blood drawing was performed. The day of blood collection, participants were informed again about the nature of the study. A total of 136 nongovernmental organizations helped us in this study, including syndicates and health-related, environmental, cultural, sporting, medical, ambientalist, professional, religious, and social groups. These organizations were very important, especially for the collection of samples in indigenous communities.
We included healthy men and women aged between 18 and 70 years. For indigenous and mestizo populations, we included only 1 family member. To be studied, indigenous subjects had to belong to one of the several ethnic groups living throughout Mexico. These were considered as indigenous when they fulfilled all of the following criteria: (1) speaking a native language as first language (with Spanish as a second language), (2) living in an indigenous village, (3) considering themselves as indigenous, and (4) being carriers of blood group O Rh(o)D-positive. 14 If an interethnic indigenous mixture was demonstrated, the subject continued to be eligible. All mestizo individuals living in Mexico were included. We excluded subjects with no evidence of mestizaje (mixing of races) in at least 1 of the parents. In addition, we excluded individuals with a history of thrombotic events or hemophilia, individuals with a family history of thrombosis or hemorrhagic diseases, and individuals with liver disease, moderate-to-severe alcoholism, or moderate-to-severe malnutrition. Finally, we excluded all women taking oral contraceptives.
Sample Collection
From each subject, 3 mL of blood was drawn in a siliconized glass tube containing 0.109M sodium citrate (9:1, vol:vol) as well as 5 mL of blood in a glass tube containing ethylenediaminetetraacetic acid (EDTA; Vacutainer, Beckton Dickinson, Franklin Lakes, New Jersey). After withdrawal, samples were centrifuged immediately at 2000 g for 15 minutes to obtain 2 aliquots of citrated plasma and 1 aliquot of buffy coat from the tube with EDTA. Aliquots were maintained in 1.5-mL Eppendorf tubes (Eppendorf AG, Hamburg, Germany) and frozen with dry ice as soon as possible. On arrival at our center, the aliquots were maintained frozen at −70°C until processing. Blood group was determined by means of blood cells.
Activated Protein C Resistance Assay
This test was performed according to the technique previously described in the literature, using a commercially available kit (Stago APC-R, Diagnostica Stago, Ansnieres, France) that measures clotting time after venom activation of factor X in the presence of activated protein C (APC); test plasma was diluted (1:20) in FV-deficient plasma. We used STA-Compaq equipment (Diagnostica Stago). Plasmas were thawed on the day of the test. Results are expressed as clotting times, without reference to baseline without APC.
We considered the test positive for APCR when clotting time was less than 120 seconds. Whenever APCR was reported as positive, the test was conducted again with a second assay performed after dilution (1:4) of test plasma in a FV plasma reagent (Coatest, APC Resistance V, Instrumentation Laboratory, Milan, Italy). Using this assay, APCR was positive when the ratio of clotting times was 0.84 or less. Whenever a subject was positive after both assays, lupus anticoagulant was excluded using a commercially available test (Staclot LA,Diagnostica Stago).
In all APCR-positive patients, a new sample was obtained at least 3 months after the first sample to confirm the result and to identify those who were likely acquired-APCR carriers. During this second study phase, APCR was again investigated using the 2 previously mentioned assays. Acquired APCR was considered according to previously published criteria as the presence of APCR in the absence of FV Leiden mutation. 13, 15 Factor V Leiden Assay
We followed the internationally accepted procedure for establishing the presence of this mutation. 16 We used the buffy coat obtained from the blood sample collected in EDTA. Genomic DNA was isolated according to the manufacturer's instructions with a QIAamp blood kit (QIAGEN, Hilden, Germany). Polymerase chain reaction (PCR) was performed in a PerkinElmer thermocycler (PerkinElmer Life and Analytical Sciences, Inc. Waltham, Massachusetts) for 30 cycles consisting of 9°C for 40 seconds, 58°C for 40 seconds, and 71°C for 2 minutes, this cycle repeated 35 times. After allele-specific restriction enzyme digestion of the amplified DNA with the restriction enzyme Mnl-l for 6 hours at 37°C, the FV Leiden genotype was identified on 3% agarose gels. These were stained with 1-μg/mL ethidium bromide and visualized under ultraviolet light. Individuals without FV Leiden mutation were identified by bands at 163 bp, 67 bp, and 37 bp. Whenever FV Leiden was present, 2 bands were visualized: one at 200 bp and the other at 67 bp.
Statistical Analysis
To detect frequencies of 2% with a 95% confidence interval and considering the entire Mexican population of 100 million, a sample of 4200 subjects was calculated; we collected and analyzed 4345 samples. Because approximately 12% of the Mexican population is indigenous, 17 we attempted to study 504 native individuals. Because 85% of the mestizaje in Mexico have Spanish origin, we attempted to sample the population while maintaining this proportion. Data are expressed as frequencies, medians, and ranges.
Because this was a nonrandomized study, we analyzed the distribution of the participating individuals to determine if there were differences among the populations that could affect the study results. We therefore analyzed the results according to the 3 main sources of recruitment of the participating individuals (universities, nongovernmental organizations, and governmental blood banks) in terms of age, sex, and prevalence of acquired APCR and FV Leiden. A χ 2 test was used to identify differences among these 3 sources of individuals. To demonstrate differences among the 3 groups in terms of age, an analysis of variance test was used. Results were significant at P < .05.
Ethics Aspects
Before blood withdrawal, all individuals received oral and written information about the study characteristics. If they agreed to participate, we requested written consent from each person. We ensured the restricted nature of results information and sample use according to Declaration of Helsinki principles. This project was approved by the Ethics Committees of our respective institutions.
Results
After 5026 healthy Mexican individuals were directly invited to participate, we obtained blood samples from 4345 subjects from throughout Mexico. General characteristics of these subjects are summarized in Table 1 . We covered all the states of the Mexican Republic, collecting blood samples from subjects in 647 cities, towns, and villages. Percentages of women and men were 51.4 and 48.6%, respectively. The median ages were 38.5 years (range, 18-68 years) for women and 40.0 years (range, 18-69 years) for men. We obtained 600 blood samples from Mexican indigenous persons residing in 11 states of the Mexican Republic and 3745 blood samples from mestizos. We obtained samples from 380 native women and 220 men, with a respective median age of 35.5 years (range, 18-56 years) and 39 years (range, 19-57 years). For mestizo individuals, median age was 40 years (range, 18-68 years) for women and 41 years (range, 18-69 years) for men. Absolute numbers and percentages of individuals sampled from each mestizo group are presented in Table 2 .
General demographic data of indigenous Mexican populations studied are presented in Table 3 . We obtained samples from 19 ethnic groups. More samples from women were obtained because they were more accessible than men, mainly because of work conditions. The O-positive blood group was found in 100% of our indigenous sample.
The APCR prevalence was 0% in the indigenous population studied. Among 3745 mestizos, APCR was found in 82 individuals (2.18%) by using 2 APCR assays. This group, which consisted of 51 women and 31 men, had a median age of 37 years (range, 18-60 years). In these individuals, APCR was investigated again by using 2 assays, as previously described. In this second sample, 50 subjects (1.33%), consisting of 35 women and 15 men, had a negative test result.
None of these women were taking hormonal medication at time of sampling, and none of the 50 subjects was a FV Leiden carrier. After the second APCR screening, 32 subjects (16 women and 16 men) remained positive, and all were positive for the FV Leiden assay; therefore, the ratio for acquired/hereditary prevalence in our study was 1.5:1. According to these data, FV Leiden prevalence in the mestizo Mexican population is as low as 0.85%. Figure 1 shows APCR distribution and the geographic distribution of FV Leiden in Mexico.
Analysis of the distribution of the individuals evaluated in this study according to the source of recruitment revealed that allocation was not significantly different in terms of age or sex (Table 4 ). Also, analysis of the distribution of cases with acquired APCR or FV Leiden according to the 3 sources of recruitment showed no differences in terms of age or FV Leiden prevalence. As expected for the total number of cases of acquired APCR found in women, prevalence of this phenomenon was significantly higher in women than in men in all 3 groups of analysis (Table 5 ). However, no significant differences were found among the 3 sources of recruitment when we separately analyzed men or women (Table 5 ). Finally, we analyzed the distribution of cases with acquired APCR or FV Leiden according to age of the participants (Table 6 ). Except for the group of individuals aged older than 61 years, distribution of cases with acquired APCR was very similar through the analysis for both variables studied.
Discussion
Arterial and venous thrombosis is the leading cause of morbidity and mortality worldwide; therefore, basic, clinical, and epidemiologic studies leading to the identification of new prothrombotic pathways are of priority. Because FV Leiden is present in up to 50% of patients with a history of thrombosis, APCR and FV Leiden continue to represent attractive issues to explore in many countries, especially in Europe. [8] [9] [10] [11] 18, 19 Haplotype analyses using 6 dimorphic sites in the FV gene in Caucasian subjects of Jewish, Arab, Austrian, and French origin support a single origin for this mutation. 20 Nonetheless, as one moves from Europe to the East, it is clear that FV Leiden prevalence decreases. Indeed, this mutation possesses an uneven geographic distribution; thus, although it is relatively common in Europe, with a prevalence in the general population of 0.8% to 13.3%, it is rare in Asia and the Middle East. 2,21-24 It has been hypothesized that this mutation probably occurred 21 000 to 34 000 years ago, after the separation of non-African progenitors from Africans (ca 100 000 years ago) and the separation of Asian progenitors from Caucasians (ca 60 000-40 000 years ago). 25, 26 Therefore, the mutation appeared somewhere in Europe after migration to America was completed. Our results strongly support this theory, because FV Leiden does not exist in the indigenous Mexican population. Notwithstanding this, we should not dismiss the possibility that FV Leiden was already present before migration but that it slowly disappeared during this human phenomenon.
The original world distribution of FV Leiden was disrupted again by modern human migrations. As a consequence, mestizaje changed the thrombophilic patterns characteristic of most of the current populations worldwide. For example, FV Leiden is nearly nonexistent in African populations; nevertheless, it rises significantly in the African American population. Of course, migration of Europeans to the Americas, and the mestizaje generated in most countries in the Americas at present, determined a new FV Leiden distribution in America.
Although previous reports found that FV Leiden was very low or absent in native Americans, 23, 27 none of these reports included the number of ethnic groups or the number of subjects as we have in our study. Our data confirm that FV Leiden is absent in indigenous American populations. In Latin American-mestizo populations, FV Leiden prevalence differs widely. In Argentina and Brazil, it reached 2.5% and 2.0%, respectively, very close most European populations. 28 Because the general prevalence of FV Leiden in Spain is between 3.3% and 3.7%, 29, 30 and because 85% of the Mexican population has Spanish mestizaje, we initially expected a similar prevalence in Mexico. A surprising finding in our study was a low prevalence of 0.85%. Because FV Leiden is absent in the native Mexican population, FV Leiden prevalence in the mestizo population strongly suggests that although this mutation was imported during the colonization of America, its current low prevalence is due to a high mixture with native populations. According to this, it appears that at least for this specific aspect of Mexican genetics, the indigenous heritage in the mestizo population is quite high.
In our study, distribution of APCR and FV Leiden exhibited a highly localized pattern. Some possible explanations for this may be based on local mestizaje patterns; for example, most Mexican states in which positive results were found either have a low number of ethnic groups or a low mestizaje index. Although Chiapas, for example, is the richest state in terms of ethnic groups, it is also true that mestizaje has been always minimal in Chiapas because of sociocultural reasons, especially in the region where most of the sampling was conducted. The third cluster of cases with APCR and FV Leiden was Mexico City. This fact appears easiest to explain because this is the city with the highest demographic concentration in the country: a giant mosaic puzzle of indigenous and mestizo individuals.
Because this was not a nonrandomized study, it is possible that our results may not be strong enough to elaborate some conclusions. To eliminate as many selection biases as possible associated with the study design, we analyzed the distribution of the participating individuals. We noticed that there were 3 major sources of recruitment of the samples; therefore, we performed several analyses from the perspective of these groups. Distribution of individuals according to age or sex was not significantly different among these 3 sources of recruitment, and there were no significant differences in terms of prevalence of FV Leiden.
Also, acquired APCR prevalence was similar among the sources of individuals when women and men were separately analyzed. We believe that all these data support the assumption that the study design did not affect the final results of the study. On the other hand, it should be noticed that a higher prevalence of acquired APCR was found in women than in men. This significantly higher prevalence of acquired APCR in women not associated with a similar increase in the prevalence of FV Leiden suggests that the mechanism(s) responsible for this phenomenon is likely associated with specific factors present in women. The significance of APCR occurring in the absence of mutations of the FV gene, also called acquired APCR, is well recognized, although information about it remains scarce. Owing to the number of potential confounders, only a few studies have analyzed APCR as an independent thrombotic risk factor. Subjects within the highest quintile of APCR have an increased risk of stroke compared with those in the lowest quintile, without significant changes after correction for FV Leiden status. 31 A population study observed a relationship between quintiles of APCR and peripheral artery disease; again, no difference was observed after adjustment for FV Leiden. 32 This finding was not unexpected owing to the association between APCR and thrombosis in nonwhite populations in which FV mutations are nearly absent. 33 Two additional surveys also observed increased risk of venous thrombosis among subjects with acquired APCR. 34, 35 Although acquired APCR prevalence has been underestimated, a study representative of a Central European population found APCR prevalence was at least as frequent as FV Leiden itself. 32 In the population-based Vicenza Thrombophilia and Arteriosclerosis Project, FV Leiden and APC ratios of 0.84 and below occurred at a ratio of 1:4. 36 It therefore appears that APCR in itself is an independent prothrombotic phenotype and that the thrombophilic state it induces should receive greater emphasis in clinical practice in the future.
Several mechanisms have been proposed to explain the phenomenon of acquired APCR in different clinical settings; however, a clear explanation is not yet available. Conditions such as lupus anticoagulant, anticardiolipin and anti-β2-glycoprotein I antibodies, 37, 38 systemic lupus erythematosus, 39 pregnancy, [40] [41] [42] acquired immunodeficiency syndrome, 43 arterial hypertension, 44 oral contraceptive intake, [45] [46] [47] oral hormone replacement therapy, 48 multiple myeloma, 15, 49 and cancer 50-52 can induce acquired APCR; thus, the plasma assay can afford misleading results additionally in the absence of FV Leiden. 53, 54 Because the originally described test based on the activated partial thromboplastin time is not specific for FV Leiden, many strategies have been devised to render coagulationbased APCR assays more specific for FV Leiden. 55 The nature of our research led us to use an FV-specific assay as global screening, and in subjects with a positive test result, a second assay using a different technical principle was chosen. No woman with a positive test result for APCR was taking hormonal drugs.
It is noteworthy that only 31% of APCR carriers were also FV Leiden carriers. It has been suggested that a high number of healthy individuals without a family history of thrombosis may be carriers of this phenotype. Of course, the non-FV Leiden APCR phenotype can be due to other rare FV mutations or to a true acquired condition. However, the prevalence of other FV mutations responsible for the inherited APCR is so low that they may be considered irrelevant. 15 In our transversal analysis, prevalence of acquired APCR reached 1.33%. We consider these individuals as true carriers of acquired APCR because (1) they had an initial positive test as evaluated by 2 different assays; (2) they had a negative test at least 3 months after the first assay, again using the same 2 assays (undoubtedly, these 2 facts strongly support the transient and noninheritable nature of the phenomenon); (3) as expected, all cases with APCR in the first and second study phases were FV Leiden carriers; and (4) all patients with transient APCR had a negative FV Leiden test result. Absence of known diseases when APCR was positive confirms that this phenomenon may be present with moderate prevalence during brief time periods in healthy subjects.
Conclusion
Our results show a very low prevalence of APCR and FV Leiden in Mexico. Based on the number of native American individuals from several ethnic groups, we confirmed that neither APCR nor FV Leiden affect native Americans. This fact strongly supports the hypothesis of the appearance of FV Leiden after migration from Europe began. We have shown that in the general population in Mexico, there exist no FV gene mutations that are different from the Leiden abnormality. Mutations in the FV gene are responsible for solely 31% of cases with APCR, signifying that acquired APCR is nearly twice as prevalent as the inherited variant. Of course, the clinical importance of this data requires clarification in specifically designed studies to evaluate its impact on thrombosis. On the basis of our data, it is possible to suggest that at least for ACPR and FV Leiden, there is a profound indigenous effect on mestizo population in Mexico.
